Abstract:2-Deoxy-D-glucose (2-DG) is a glucose analog used as a promising anticancer agent. It exerts its effects by inhibiting the glycolytic energy metabolism to deplete cells of energy. The larval stage of Echinococcus relies on glycolysis for energy production. Therefore, in this study, we investigated the in vitro and in vivo efficacy of 2-DG against the larval stage of Echinococcus granulosus and E. multilocularis. 2-DG exhibited significant time- and dose-dependent effects against in vitro cultured E. granulosus protoscoleces and E. multilocularis metacestodes. A daily oral administration of 500 mg/kg 2-DG in E. multilocularis-infected mice effectively reduced the weight of metacestodes. Notably, the combination treatment, either 2-DG (500 mg/kg/day) + albendazole (ABZ) (200 mg/kg/day) or 2-DG (500 mg/kg/day) + half-dose of ABZ (100 mg/kg/day), exhibited a potent therapeutic effect against E. multilocularis, significantly promoting the reduction of metacestodes weight compared with the administration of 2-DG or ABZ alone. Furthermore, the combination significantly promoted apoptosis of the cells of metacestodes and inhibited glycolysis in metacestodes, compared with the administration of 2-DG or ABZ alone. In conclusion, 2-DG exerts an effective activity against the larval stage of Echinococcus. Thus, it may be a promising anti-Echinococcus drug, and its combination with ABZ may provide a new strategy for the treatment of echinococcosis in humans. Author summary Echinococcosis is a serious but neglected helminthic zoonosis caused by the larval stage of Echinococcus granulosus and E. multilocularis. At present, clinical pharmacotherapy of echinococcosis, such as albendazole (ABZ) and mebendazole, has limited effectiveness. Thus, the development of novel therapeutic drugs for human echinococcosis is urgently needed. 2-Deoxy-D-glucose (2-DG) is a glucose analog used as a promising anticancer agent, and it exerts its effects by inhibiting the glycolytic energy metabolism to deplete cells of energy. Echinococcus in the host depends on glycolysis for energy production and glycolysis intermediates for other metabolic processes. Therefore, in this study, we investigated the efficacy of 2-DG against Echinococcus. 2-DG exerted an effective in vitro and in vivo activity against E. granulosus protoscoleces and E. multilocularis metacestodes, and the combination of this drug with ABZ further improved the therapeutic effect. Therefore, 2-DG can be developed as a promising anti-Echinococcus drug, and its combination with ABZ may provide a new strategy for the treatment of human echinococcosis in the future.

In Vitro Effects of Lonidamine and 6-Aminonicotinamide Against Echinococcus Granulosussensu Stricto and Echinococcus Multilocularis

In Vivo and in Vitro Studies of Cry5B and Nicotinic Acetylcholine Receptor Agonist Anthelmintics Reveal a Powerful and Unique Combination Therapy Against Intestinal Nematode Parasites

In Vitro Efficacy of Ampelopsin Against Echinococcus Granulosus and Echinococcus Multilocularis

An Extensive Comparison of the Effect of Anthelmintic Classes on Diverse Nematodes

Effect of Anacardic Acid Against Echinococcosis Through Inhibition of VEGF-induced Angiogenesis

Discovery of a Highly Synergistic Anthelmintic Combination That Shows Mutual Hypersusceptibility

Efficacy of Osthole for Echinococcus Granulosus in Vitro and Echinococcus Multilocularis in Vivo

Efficacy and mechanism of energy metabolism dual-regulated nanoparticles (atovaquone-albendazole nanoparticles) against cystic echinococcosis

In Vitro and in Vivo Efficacies of the EGFR/MEK/ERK Signaling Inhibitors in the Treatment of Alveolar Echinococcosis

2-Deoxy-D-glucose and combined 2-Deoxy-D-glucose/albendazole exhibit therapeutic efficacy against <i>Echinococcus granulosus</i> protoscoleces and experimental alveolar echinococcosis

In Vivo and in Vitro Efficacies of Mebendazole, Mefloquine and Nitazoxanide Against Cyst Echinococcosis

HIV protease inhibitor nelfinavir is a potent drug candidate against echinococcosis by targeting Ddi1-like protein

Current Status of Drug Therapy for Alveolar Echinococcosis

In Vitro Effects of Amino Alcohols on Echinococcus Granulosus

In vivo effect of magnetic microspheres loaded with E2-a in the treatment of alveolar echinococcosis

1,3-Substituted Β-Carboline Derivatives As Potent Chemotherapy for the Treatment of Cystic Echinococcosis.

Evaluation of Allicin Against Alveolar Echinococcosis in Vitro and in a Mouse Model

Ubenimex Combined with Albendazole for the Treatment of Echinococcus Multilocularis-Induced Alveolar Echinococcosis in Mice

Effects of Echinococcus Multilocularis Metacestodes Infection and Drug Treatment on the Activities of Biotransformation Enzymes in Mouse Liver

Repurposing of a library for high-content screening of inhibitors against Echinococcus granulosus

Advances in the pharmacological treatment of hepatic alveolar echinococcosis: From laboratory to clinic